期刊
MOLECULAR PHARMACOLOGY
卷 92, 期 5, 页码 519-532出版社
AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
DOI: 10.1124/mol.117.109017
关键词
-
资金
- Live Cell Imaging Facility - Snyder Institute at the University of Calgary
Transforming growth factor-beta (TGF-beta), serine proteinases such as trypsin, and proteinase-activated receptor 2 (PAR2) promote tumor development by stimulating invasion and metastasis. Previously, we found that in cancer cells derived from pancreatic ductal adenocarcinoma (PDAC) PAR2 protein is necessary for TGF-beta 1-dependent cell motility. Here, we show in the same cells that, conversely, the type I TGF-beta receptor activin receptor-ike kinase 5 is dispensable for trypsin and PAR2 activating peptide (PAR2-AP)-induced migration. To reveal whether Gq-calcium signaling is a prerequisite for PAR2 to enhance TGF-beta signaling, we investigated the effects of PAR2-APs, PAR2 mutation and PAR2 inhibitors on TGF-beta 1-induced migration, reporter gene activity, and Smad activation. Stimulation of cells with PAR2-AP alone failed to enhance basal or TGF-beta 1-induced C-terminal phosphorylation of Smad3, Smad-dependent activity of a luciferase reporter gene, and cell migration. Consistently, in complementary loss of function studies, abrogation of the PAR2-G(q)-calcium signaling arm failed to suppress TGF-beta 1-induced cell migration, reporter gene activity, and Smad3 activation. Together, our findings suggest that the calcium-regulating motif is not required for PAR2 to synergize with TGF-beta 1 to promote cell motility. Additional experiments in PDAC cells revealed that PAR2 and TGF-beta 1 synergy may involve TGF-beta 1 induction of enzymes that cause autocrine cleavage/activation of PAR2, possibly through a biased signaling function. Our results suggest that although reducing PAR2 protein expression may potentially block TGF-beta's prooncogenic function, inhibiting PAR2-G(q)-calcium signaling alone would not be sufficient to achieve this effect.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据